

## Journal of Hepatology

### CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

|  |
|--|
|  |
|--|

#### 1.1 Antibodies

| Name | Citation | Supplier | Cat no. | Clone no. |
|------|----------|----------|---------|-----------|
|      |          |          |         |           |

#### 1.2 Cell lines

| Name | Citation | Supplier | Cat no. | Passage no. | Authentication test method |
|------|----------|----------|---------|-------------|----------------------------|
|      |          |          |         |             |                            |

#### 1.3 Organisms

| Name | Citation | Supplier | Strain | Sex | Age | Overall n number |
|------|----------|----------|--------|-----|-----|------------------|
|      |          |          |        |     |     |                  |

#### 1.4 Sequence based reagents

| Name | Sequence | Supplier |
|------|----------|----------|
|      |          |          |

#### 1.5 Biological samples

| Description                                                        | Source                                                 | Identifier                                                                         |
|--------------------------------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------|
| Serum samples of patients following APAP-ALF days 1-2 and days 3-5 | United States Acute Liver Failure Study Group Registry | Samples from all 196 patients have unique reference numbers – available on request |

#### 1.6 Deposited data

| Name of repository | Identifier | Link |
|--------------------|------------|------|
|                    |            |      |

## 1.7 Software

| Software name             | Manufacturer        | Version             |
|---------------------------|---------------------|---------------------|
| Prism                     | GraphPad            | V8.4.2              |
| Stata                     | Statacorp           | 16.0                |
| Metacore Pathway Analysis | Clarivate Analytics | Accessed April 2020 |
| LightCycler 480 software  | Roche               | 4.0                 |

## 1.8 Other (e.g. drugs, proteins, vectors etc.)

|                                       |                         |
|---------------------------------------|-------------------------|
| miRCURY RNA isolation kit - biofluids | Qiagen, Hilden, Germany |
| miRCURY LNA RT kit                    | Qiagen, Hilden, Germany |
| miRCURY Ready-to-Use PCR custom panel | Qiagen, Hilden, Germany |
| miRCURY LNA SYBR Green master mix     | Qiagen, Hilden, Germany |

## 1.9 Please provide the details of the corresponding methods author for the manuscript:

Dr OD Tavabie. Institute of Liver Studies, King's College Hospital, London UK SE5 9RS. Email:- [oliver.tavabie@nhs.net](mailto:oliver.tavabie@nhs.net) Phone:+44 20 3299 4017 Fax: +44 20 3299 3167

## 2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

Not applicable